ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule
LEUVEN, Belgium, June 25 /PRNewswire-FirstCall/ --
- Recruitment on Track for ThromboGenics' Lead Product for the
Non-Surgical Treatment of Eye Disease With No Reported Safety Issues
ThromboGenics NV (Euronext Brussels: THR), a biotechnology company
focused on the discovery and d...
Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting
Phase 1 Data Demonstrate Safety and Evidence of Biological Activity in 9 of 12 Patients;
Phase 2 Study Currently Enrolling in 17 Leading U.S. Medical Centers
SAN DIEGO, May 28 /PRNewswire/ -- Celladon Corporation presented today Phase 1 data from the Calcium Up-Regulation by Percutaneou...
National Hemovigilance Pilot Program Launches to Track Adverse Events Associated with Blood Transfusion
Goal is to Enhance Patient Safety and Reduce Health Care Costs
BETHESDA, Md., May 7 /PRNewswire-USNewswire/ -- Beginning today, nine hospitals will join in a pilot program, contributing data on adverse events associated with blood transfusions. By analyzing the data collected, it w...
Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
Two Phase 3 studies to start in the second half of this year
BERLIN and TARRYTOWN, N.Y., April 30 /PRNewswire-FirstCall/ -- Bayer HealthCare AG and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) today announced that the companies are extending their global development program
for VEGF Trap...
Drug Development Program Started Based on CAP(R) Human Cell Line
COLOGNE, Germany, March 3 /PRNewswire/ --
- New Platform May Provide Solutions for Many RA-Patients Around the World
Alloksys Life Sciences BV (Bunnik, The Netherlands), CEVEC
Pharmaceuticals GmbH (Cologne, Germany) and PharmaCell BV (Maastricht, The
Netherlands) announce the sta...
SGO and ACOG Announce Breast Cancer Fellowship Program for Gynecologic Oncologists
CHICAGO, March 2 /PRNewswire-USNewswire/ -- The Society of Gynecologic Oncologists (SGO) and the American College of Obstetricians and Gynecologists (ACOG) have jointly developed a breast disease fellowship training program
for gynecologic oncologists. Supported by a grant of $75,000 fr...
Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference
VLP Vaccine - Coupled with Innovative Manufacturing - Has Potential to Address Gaps in Global Pandemic Preparedness
ROCKVILLE, Md., Feb. 17 /PRNewswire-FirstCall/ -- At the 5th World Health Organization Meeting on Evaluation of Pandemic Influenza Prototype Vaccines in Clinical Trials, Novavax...
Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
SEATTLE, Feb. 10 /PRNewswire-FirstCall/ -- Cell Therapeutics (CTI) (NASDAQ and MTA: CTIC) today announced that they have executed a definitive collaborative agreement with IDIS to manage its investigational drug pixantrone on a named patient basis in Europe. Pixantrone will be supplied by IDIS to...
InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
BRISBANE, Calif., Feb. 2 /PRNewswire-FirstCall/ -- InterMune, Inc.
(Nasdaq: ITMN ) today announced that it will report results from its Phase 3
of pirfenidone in idiopathic pulmonary fibrosis (IPF) prior
to market open on Tuesday, February 3. InterMune will conduct a confer...
AGA Medical Corporation Launches Web-Based Stroke Education and Awareness Program Featuring Professional Football Player Tedy Bruschi
MINNEAPOLIS, Jan. 29 /PRNewswire/ -- AGA Medical Corporation today launched a web-based stroke education and awareness program
featuring Tedy Bruschi, a professional football player who suffered a stroke in February 2005, subsequently recovered and returned to his career. The unique online educati...
Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer
OSLO, Norway, January 14 /PRNewswire-FirstCall/ --
- Results Highlight the Potential of Alpharadin to Treat Bone Metastases
in Major Cancer Indications
Algeta ASA (OSE: ALGETA), the cancer therapeutics company, announces that
with the results of the BC1-04 study reported today i...
ProFibrix Steps up Recombinant Fibrinogen Program With PER.C6(R) License From Crucell
LEIDEN, The Netherlands, January 13 /PRNewswire/ -- ProFibrix B.V., today
announced that it has concluded a commercial license agreement with Crucell
N.V. (Euronext, NASDAQ: CRXL ; Swiss Exchange: CRX) for PER.C6(R), a unique
human protein production platform. The PER.C6(R) platform allows P...
ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
LEUVEN, Belgium, January 9 /PRNewswire-FirstCall/ --
- ThromboGenics' Lead Product to be Studied in the Treatment of
Vitreomacular Adhesion in the US and Europe
ThromboGenics NV (Euronext Brussels: THR), a biotechnology company
focused on innovative treatments for eye disease, va...
Celtic Pharma Announces Update on Status of XERECEPT(R) Program Sale Planned in 2009
NEW YORK, LONDON and HAMILTON, Bermuda, Dec. 16 /PRNewswire/ -- Celtic Pharmaceutical Holdings L.P. ("Celtic Pharma") announced today that the databases have been locked and preliminary analyses completed on the two double-blinded studies of XERECEPT (R) (corticorelin acetate), as a treatment fo...
Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer
PRINCETON, N.J., Nov. 24 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) today announced it has initiated a Phase 1b clinical trial for MDX-1106 (ONO-4538: development code of Ono Pharmaceutical Co., Ltd.), a fully human anti-PD-1 antibody for the treatment of cancer. Studies suggest t...
Healthy Bones Program Reduces Hip Fractures by 37 Percent, Kaiser Permanente Study Finds
Largest Study of Its Kind
PASADENA, Calif., Nov. 4 /PRNewswire/ -- Proactive measures can reduce
hip fracture rates by an average of 37.2 percent -- and as much as 50
percent -- among those at risk, according to a study conducted by Kaiser
Permanente Southern California....
MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine
GAITHERSBURG, Md., Nov. 3 /PRNewswire/ -- MedImmune today announced
that it has initiated a Phase 1/2a clinical trial of a live, attenuated
intranasal vaccine in healthy children one month to 12 months of age to
help prevent severe respiratory syncytial virus (RSV) infections. RSV is
the most ...
Susan G. Komen for the Cure(R) Makes Unprecedented Research and Local Program Grants
DETROIT, Oct. 14 /PRNewswire-USNewswire/ -- Susan G. Komen for the
Cure(R) recently announced the distribution of an unprecedented $100
million in grants to American and international scientists this year alone
to fast track breast cancer research. Grants were also made by local Komen
Good Samaritan Hospital Launches High Risk Breast Cancer Program at Good Samaritan North Health Center
Advances in diagnostics and genetic testing give women answers about their risks
DAYTON, Ohio, Oct. 1 /PRNewswire/ -- According to the U.S. Cancer
Statistics Working Group (2007), an estimated 182,460 new cases of breast
cancer will be diagnosed in American women...
Unprecedented 8th Year Start Up of National Direct AmeriCorps Program Access to Care Through Service (ACTS) Parent, Lead Organization The Philadelphia AIDS Consortium and World Health Care Infrastructures
PHILADELPHIA, Sept. 30 /PRNewswire-USNewswire/ -- The following is
being released by The Philadelphia AIDS Consortium:
WHO: Parent Organization: The Philadelphia AIDS Consortium in
partnership with its network of eleven (11) community-based organization
sites located throughout the tri-state...
Nutrition 21 Reports That National Toxicology Program Studies Support the Safety of Chromium Picolinate
PURCHASE, N.Y., Sept. 11 /PRNewswire-FirstCall/ -- Nutrition 21, Inc.
(Nasdaq: NXXI ), the developer and marketer of nutritional supplements under
the Iceland Health Chromax(R), and Diabetes Essentials(TM) brands that help
consumers manage blood sugar levels, improve cardiovascular health, en...
Rabies Vaccination Program Underway in Western Pennsylvania
HARRISBURG, Pa., Sept. 2 /PRNewswire-USNewswire/ -- An annual program
that helps control rabies in wild animals is underway in western
Pennsylvania, Agriculture Secretary Dennis Wolff said today.
The oral rabies vaccination baiting program
covers all or parts of
Allegheny, Armstrong, Beaver,...
Calabar AB Today Announced New Financing for Continuation of the Phase II Program in Patients With Dry Mouth
GOTEBORG, Sweden, September 1 /PRNewswire/ -- Calabar AB, a privately
held pharmaceutical company developing therapies for treating dry mouth,
today announced a EUR 350,000 equity financing from the investment company
Karolinska Development AB. The financing will take Calabar's product
Telik's Proteasome Inhibitor Program Meets a Preclinical Development Milestone
PALO ALTO, Calif., Aug. 21 /PRNewswire-FirstCall/ -- Telik, Inc.
(Nasdaq: TELK ) announced today that its novel small molecule proteasome
met a preclinical development milestone by demonstrating
anticancer activity in preclinical models of human leukemia. The proteasome
Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
Medarex to Receive Milestone Payment from MedImmune
PRINCETON, N.J., Aug. 12 /PRNewswire-FirstCall/ -- Medarex, Inc.
(Nasdaq: MEDX ) announced today that its partner MedImmune, Inc. has
initiated a Phase 2A multi-dose clinical trial of MEDI-545 for the
potential treatment of systemi...
Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
CAMBRIDGE, Mass., Aug. 5 /PRNewswire/ -- Tolerx, Inc., a
biopharmaceutical company engaged in the discovery and development of novel
therapies for the treatment of immune-mediated diseases, announced today
that Genentech, a collaborator, has moved a modified version of TRX1,
MTRX1011A, an anti...
Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
~ Initiates IDX184 Phase I Clinical Study and Advances HCV Protease
Inhibitor and Non-Nucleoside Polymerase Inhibitor Clinical Candidates into IND-Enabling Preclinical Studies ~
CAMBRIDGE, Mass., July 29 /PRNewswire-FirstCall/ -- Idenix
Pharmaceuticals, Inc. (Nasdaq: IDIX...
Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
SAN DIEGO, July 28 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals,
Inc. (Nasdaq: CADX ), a biopharmaceutical company focused on in-licensing,
developing and commercializing proprietary product candidates principally
for use in the hospital setting, today announced that it will release its
Small Business Innovation Research Program Awards Grant to Biomoda
Company developing proposals to fund clinical studies for early detection of lung cancer
ALBUQUERQUE, N.M., June 25 /PRNewswire-FirstCall/ -- Biomoda, Inc. (OTC
Bulletin Board: BMOD) ( http://www.biomoda.com ), a development stage medical
diagnostics company, announc...
Pharmaxis Establishes Named Patient Program for Bronchitol
SYDNEY, Australia, June 16 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis
(ASX: PXS; Nasdaq: PXSL) today announced the appointment of IDIS Limited to
manage and provide eligible patients worldwide with access to Bronchitol
through a Named Patient Program.
will allow patients who are ...
Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
Olympus Corporation to Support the Joint Program
through the Provision of Novel Imaging Systems
Collaboration Will Bring Innovative Fluorescent Imaging Agent and System Technologies into Clinical Trials in Ovarian Cancer
PHILADELPHIA, TOKYO and WOBURN, Mass, J...
Transdel Initiates Ketotransdel(TM) Phase 3 Clinical Program for Pain
Cato Research Signed as Strategic Partner for the Phase 3 Program
LA JOLLA, Calif., June 16 /PRNewswire-FirstCall/ -- Transdel
Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP), a specialty
pharmaceutical company developing non-invasive, topically administered
medications, today announced th...
Radius Selects First Preclinical Candidate From SARM Discovery Program for the Treatment of Muscle Loss and Other Musculoskeletal Conditions
CAMBRIDGE, Mass., June 9 /PRNewswire/ -- Radius Health ("Radius")
announced today that the company has selected the first lead candidate,
RAD140, from its internal nonsteroidal selective androgen receptor
modulator ("SARM") discovery program, for full preclinical development as a
Heart Patients More Likely to Adopt Healthy Habits in 3-Year Program Led by Cardiac Rehabilitation Experts, Mayo Clinic Research Shows
ROCHESTER, Minn., June 4 /PRNewswire-USNewswire/ -- People recovering
from acute heart problems such as heart attack and heart surgery are more
likely to develop habits to control heart attack risk factors when they
meet regularly with cardiac "disease managers," according to researchers at
Penn State Hershey Transplant Program Uses Assay to Monitor Cell-Mediated Immunity
Improvement Noted in Management of Transplant Recipients with Cancer
HERSHEY, Pa., June 1 /PRNewswire/ -- The management of
immunosuppression in post-transplant patients with cancer is challenging.
Clinicians must balance the need to treat the malignancy effectively while
Genasense(R) Chemotherapy Program Yields High Response Rate in Patients with Stage 4 Melanoma
Related Clinical Study Shows Potential Utility of Short-Course High-Dose Therapy
BERKELEY HEIGHTS, N.J., May 30 /PRNewswire-FirstCall/ -- Genta
Incorporated (OTC Bulletin Board: GNTA) announced preliminary results that
have shown a high objective response rate in...
Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting
Efficacy and safety data support potential of asenapine in the treatment of schizophrenia and bipolar I disorder
WASHINGTON, May 8 /PRNewswire-FirstCall/ -- Schering-Plough Corporation
(NYSE: SGP ) today announced that an overview of asenapine clinical trials
from the Olympia p...
Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
Phase III Clinical Trial of Acetavance(TM) for the Treatment of Fever Achieves Primary Endpoint Phase III Clinical Trial of Omigard(TM) Completes Patient Enrollment
SAN DIEGO, May 6 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals,
Inc. (Nasdaq: CADX ), a biopharmaceu...
Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
SOUTH SAN FRANCISCO, Calif., May 6 /PRNewswire/ -- Catalyst
Biosciences, Inc., a pioneer in the discovery and development of engineered
proteases known as Alterase(TM) therapeutics, announced that it has
selected CB 813, an improved, second-generation variant of human
coagulation factor VIIa, ...
Colorado Cancer Research Program Will Host Golf Event to 'Drive' the Message that Clinical Trials Play a Vital Role in the Quest to Find a Cure for Cancer
DENVER, April 28 /PRNewswire-USNewswire/ -- The Colorado Cancer
(CCRP) invites golfers to participate in its second annual
"Drive for a Cure" Golf Tournament on May 19 at the Valley Country Club,
14601 Country Club Drive, Aurora. The private club is one of Denver's